Langenfeld
Germany
10
2026-03-05
The entities that hold a legal rights for patent applications filed by inventor Eissing Thomas:
Thomas Eissing from Langenfeld, DE has applied for patents for these inventions. The list has both pending applications and granted patents:
METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE
#2 | 2026-01-29METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE
#3 | 2025-10-09METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE
#4 | 2025-10-02METHOD OF PREVENTING OR TREATING HEART FAILURE IN A PATIENT USING (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXAMIDE
#5 | 2025-01-23Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
#6 | 2024-01-25Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
#7 | 2023-09-28Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
#8 | 2023-09-21Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
#9 | 2017-11-16GENOTYPE- OR PHENOTYPE-BASED DRUG FORMULATION
#10 | 2015-06-25Genotype- or phenotype-based drug formulation
1202435 ⎘